Check Cap Ltd (CHEK) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 6 from a previous price target of $11 . Maxim Group advised their investors in a research report released on Aug 1, 2016.
Many Wall Street Analysts have commented on Check Cap Ltd. Shares were Reiterated by Chardan Capital Markets on May 20, 2016 to “Buy” and Lowered the Price Target to $ 4 from a previous price target of $6 .
Check Cap Ltd closed down -0.068 points or -5.12% at $1.26 with 26,603 shares getting traded on Friday. Post opening the session at $1.3, the shares hit an intraday low of $1.25 and an intraday high of $1.32 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for colorectal cancer (CRC) screening. The Company’s imaging capsule is designed to create a reconstructed two and three-dimensional image of the colon and to enable detection of clinical polyps. The Company’s imaging capsule consists of an X-ray source and X-ray detectors. The X-ray source is contained in a rotating radiation shield enabling the generation of 360-degree angular scans. The Company’s imaging capsule is swallowed by the patient and propelled by natural motility through the gastrointestinal tract and excreted naturally. Its imaging capsule employs X-rays which allow it to image the lining of the colon even when surrounded by intestinal content.